| Patient | Jane Austen |
|---|---|
| Date of birth | 1985-12-16 |
| Identifiers | MRN HR-EN014-SYN; SSN (made up) 000-14-6317 |
| Document date | 2026-11-01 |
| Author | Harriet Pemberton-Okafor, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for about three months of tiredness, weight loss, darkening skin, nausea and back ache, with blood tests and urgent endocrinology referral. Concerns: She has felt worn out for months and is losing weight, and her face and hands have darkened; she wants to know what is wrong; She wants enough energy to finish the novel she is revising and to walk out again. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrocortisone 10 mg oral tablet, one tablet by mouth on waking | One tablet by mouth on waking | Oral route | 2026-03-19 | active | S |
| Hydrocortisone 5 mg oral tablet, one tablet by mouth at 2 pm | One tablet by mouth at 2 pm | Oral route | 2026-03-19 | active | S |
| Fludrocortisone 0.1 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 2026-03-19 | active | S |
| Hydrocortisone 100 mg injection kit (with diluent), 100 mg into the thigh muscle once for vomiting, collapse or signs of adrenal crisis, then call 911 | Once, as needed for adrenal crisis; carry at all times | Intramuscular route | 2026-03-19 | active | S |
| Amoxicillin 500 mg oral capsule, one capsule by mouth twice daily for ten days | One capsule twice daily for ten days | Oral route | 2026-04-20 to 2026-04-29 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Cosyntropin (ACTH) stimulation test, 250 mcg intravenously with cortisol at 0, 30 and 60 minutes | 2026-03-19 to 2026-03-19 | completed | S |
| Chest X-ray, posteroanterior and lateral | 2026-03-19 to 2026-03-19 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-07-27 to 2026-07-27 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-07-27 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
| 2026-07-27 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-10-12 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 2026-10-12 | Influenza vaccine, inactivated, this season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1783 | Severe fever (described as putrid fever) as a young child at school, from which she nearly died | D (CLM-0004) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died after an illness of only forty-eight hours; cause not recorded in the cited source | D (CLM-0020) |
| Concern | Status | Evidence |
|---|---|---|
| She has felt worn out for months and is losing weight, and her face and hands have darkened; she wants to know what is wrong | active | S |
| She wants enough energy to finish the novel she is revising and to walk out again | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13.2 on 2026-10-12; MCV [Entitic mean volume] in Red Blood Cells by Automated count 90 on 2026-04-30; Leukocytes [#/volume] in Blood by Automated count 5.8 on 2026-03-16; Eosinophils [#/volume] in Blood 0.38 on 2026-04-02; Platelets [#/volume] in Blood by Automated count 262 on 2026-03-16; Sodium [Moles/volume] in Serum or Plasma 136 on 2026-04-20; Potassium [Moles/volume] in Serum or Plasma 4.7 on 2026-04-20; Chloride [Moles/volume] in Serum or Plasma 99 on 2026-03-16; Carbon dioxide, total [Moles/volume] in Serum or Plasma 21 on 2026-03-16; Urea nitrogen [Mass/volume] in Serum or Plasma 23 on 2026-03-16; Creatinine [Mass/volume] in Serum or Plasma 0.85 on 2026-10-12; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 89 on 2026-10-12; Glucose [Mass/volume] in Serum or Plasma 91 on 2026-04-20; Calcium [Mass/volume] in Serum or Plasma 10.1 on 2026-03-16; Thyrotropin [Units/volume] in Serum or Plasma 2.9 on 2026-10-12; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 on 2026-03-16; Ferritin [Mass/volume] in Serum or Plasma 64 on 2026-03-16; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 486 on 2026-03-16; Folate [Mass/volume] in Serum or Plasma 11.2 on 2026-03-16; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-10-12; Cortisol [Mass/volume] in Serum or Plasma 2.6 on 2026-03-19; Corticotropin [Mass/volume] in Plasma 548 on 2026-03-19; Cortisol [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IV rapid 3.4 on 2026-03-19; Cortisol [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IV rapid 3.9 on 2026-03-19; Renin [Enzymatic activity/volume] in Plasma 2.8 on 2026-10-12; Aldosterone [Mass/volume] in Serum or Plasma 1.8 on 2026-03-19; Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma 172 on 2026-03-19; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-07-27; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 2 on 2026-07-27; Total score [AUDIT-C] 1 on 2026-07-27; Cholesterol [Mass/volume] in Serum or Plasma 182 on 2026-07-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 68 on 2026-07-27; Triglyceride [Mass/volume] in Serum or Plasma 74 on 2026-07-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 99 on 2026-07-27; 21-Hydroxylase Ab [Units/volume] in Serum 24 on 2026-04-02; Hemoglobin A1c/Hemoglobin.total in Blood 5 on 2026-04-02; Tissue transglutaminase IgA Ab [Units/volume] in Serum 0.8 on 2026-04-02; IgA [Mass/volume] in Serum or Plasma 188 on 2026-04-02 [S]
Strengths and supports: Supports: a close bond with her sister, many nieces and nephews who write often, and work she finds absorbing [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| About three months of increasing tiredness, loss of 5 kg, darkening of the skin, nausea with bouts of vomiting, low back ache, salt craving and lightheadedness on standing, with low sodium, high potassium and raised eosinophils; adrenal insufficiency suspected and urgent endocrinology testing booked | resolved | confirmed | R53.83 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis at the consultation; its timing echoes the documented break in her health (D). |
| Primary adrenal insufficiency (Addison's disease): no cortisol response to cosyntropin with a markedly raised ACTH, and mineralocorticoid deficiency with raised renin and low aldosterone; on hydrocortisone and fludrocortisone; synthetic modern diagnosis chosen for a historical illness whose cause is disputed | active | confirmed | E27.1 | S — Synthetic modern diagnosis; the historical cause of her illness remains undetermined (R, disputed). |
| Mild normocytic anemia (hemoglobin 11.4 g/dL) with normal ferritin, vitamin B12 and folate | resolved | confirmed | D64.9 | S — Synthetic finding at intake; it recovers on replacement. |
| Group A streptococcal pharyngitis with fever, treated with amoxicillin and doubled hydrocortisone under the sick-day rules; resolved | resolved | confirmed | J02.0 | S — Synthetic intercurrent illness; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-16 | Hemoglobin [Mass/volume] in Blood | 11.4 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-03-16 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 89 | fL | 80-100 fL | Normal | S |
| 2026-03-16 | Leukocytes [#/volume] in Blood by Automated count | 5.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-16 | Eosinophils [#/volume] in Blood | 0.74 | 10*3/uL | 0-0.5 10*3/uL | High | S |
| 2026-03-16 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-16 | Sodium [Moles/volume] in Serum or Plasma | 131 | mmol/L | 135-145 mmol/L | Low | S |
| 2026-03-16 | Potassium [Moles/volume] in Serum or Plasma | 5.4 | mmol/L | 3.5-5.1 mmol/L | High | S |
| 2026-03-16 | Chloride [Moles/volume] in Serum or Plasma | 99 | mmol/L | 98-107 mmol/L | Normal | S |
| 2026-03-16 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 21 | mmol/L | 22-29 mmol/L | Low | S |
| 2026-03-16 | Urea nitrogen [Mass/volume] in Serum or Plasma | 23 | mg/dL | 7-20 mg/dL | High | S |
| 2026-03-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-03-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 79 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-16 | Glucose [Mass/volume] in Serum or Plasma | 72 | mg/dL | 70-139 mg/dL | Normal | S |
| 2026-03-16 | Calcium [Mass/volume] in Serum or Plasma | 10.1 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-16 | Thyrotropin [Units/volume] in Serum or Plasma | 3.6 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-03-16 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-03-16 | Ferritin [Mass/volume] in Serum or Plasma | 64 | ng/mL | 15-150 ng/mL | Normal | S |
| 2026-03-16 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 486 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-03-16 | Folate [Mass/volume] in Serum or Plasma | 11.2 | ng/mL | Above 5.9 ng/mL: normal | Normal | S |
| 2026-03-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-03-19 | Cortisol [Mass/volume] in Serum or Plasma | 2.6 | ug/dL | 8 am: 5 to 23 ug/dL | Low | S |
| 2026-03-19 | Corticotropin [Mass/volume] in Plasma | 548 | pg/mL | 7.2-63 pg/mL | High | S |
| 2026-03-19 | Cortisol [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IV rapid | 3.4 | ug/dL | Peak of 18 ug/dL or more excludes adrenal insufficiency (about 14 to 15 ug/dL on newer assays) | Low | S |
| 2026-03-19 | Cortisol [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IV rapid | 3.9 | ug/dL | Peak of 18 ug/dL or more excludes adrenal insufficiency (about 14 to 15 ug/dL on newer assays) | Low | S |
| 2026-03-19 | Renin [Enzymatic activity/volume] in Plasma | 16.2 | ng/mL/h | Upright, mid-morning: 0.6 to 4.3 ng/mL/h | High | S |
| 2026-03-19 | Aldosterone [Mass/volume] in Serum or Plasma | 1.8 | ng/dL | Upright, mid-morning: 4 to 31 ng/dL | Low | S |
| 2026-03-19 | Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma | 172 | U/L | 140-280 U/L | Normal | S |
| 2026-03-19 | Sodium [Moles/volume] in Serum or Plasma | 132 | mmol/L | 135-145 mmol/L | Low | S |
| 2026-03-19 | Potassium [Moles/volume] in Serum or Plasma | 5.3 | mmol/L | 3.5-5.1 mmol/L | High | S |
| 2026-04-02 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-02 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-02 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-04-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 88 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-02 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-139 mg/dL | Normal | S |
| 2026-04-02 | Hemoglobin [Mass/volume] in Blood | 11.9 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-04-02 | Eosinophils [#/volume] in Blood | 0.38 | 10*3/uL | 0-0.5 10*3/uL | Normal | S |
| 2026-04-30 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-30 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-30 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-04-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 90 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-30 | Renin [Enzymatic activity/volume] in Plasma | 3.4 | ng/mL/h | Upright, mid-morning: 0.6 to 4.3 ng/mL/h | Normal | S |
| 2026-04-30 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-04-30 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 90 | fL | 80-100 fL | Normal | S |
| 2026-10-12 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-12 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.85 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-10-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 89 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-12 | Renin [Enzymatic activity/volume] in Plasma | 2.8 | ng/mL/h | Upright, mid-morning: 0.6 to 4.3 ng/mL/h | Normal | S |
| 2026-10-12 | Hemoglobin [Mass/volume] in Blood | 13.2 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-10-12 | Thyrotropin [Units/volume] in Serum or Plasma | 2.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-10-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-04-20 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-20 | Glucose [Mass/volume] in Serum or Plasma | 91 | mg/dL | 70-139 mg/dL | Normal | S |
| 2026-07-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-07-27 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 2 | {score} | S | ||
| 2026-07-27 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 2026-07-27 | Cholesterol [Mass/volume] in Serum or Plasma | 182 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-07-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 68 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-07-27 | Triglyceride [Mass/volume] in Serum or Plasma | 74 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-07-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 99 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-04-02 | 21-Hydroxylase Ab [Units/volume] in Serum | 24 | U/mL | Below 1 U/mL: negative | High | S |
| 2026-04-02 | Hemoglobin A1c/Hemoglobin.total in Blood | 5 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-04-02 | Tissue transglutaminase IgA Ab [Units/volume] in Serum | 0.8 | U/mL | Below 4 U/mL: negative | Normal | S |
| 2026-04-02 | IgA [Mass/volume] in Serum or Plasma | 188 | mg/dL | 70-400 mg/dL | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-16 | Body height | 170 | cm | S |
| 2026-03-16 | Body weight | 52 | kg | S |
| 2026-03-16 | Body mass index (BMI) [Ratio] | 18 | kg/m2 | S |
| 2026-03-16 | Systolic blood pressure | 98 | mm[Hg] | S |
| 2026-03-16 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 2026-03-16 | Heart rate | 92 | /min | S |
| 2026-03-16 | Respiratory rate | 16 | /min | S |
| 2026-03-16 | Body temperature | 37.4 | Cel | S |
| 2026-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-03-19 | Body height | 170 | cm | S |
| 2026-03-19 | Body weight | 51.8 | kg | S |
| 2026-03-19 | Body mass index (BMI) [Ratio] | 17.9 | kg/m2 | S |
| 2026-03-19 | Systolic blood pressure | 96 | mm[Hg] | S |
| 2026-03-19 | Diastolic blood pressure | 60 | mm[Hg] | S |
| 2026-03-19 | Heart rate | 94 | /min | S |
| 2026-03-19 | Respiratory rate | 16 | /min | S |
| 2026-03-19 | Body temperature | 37.3 | Cel | S |
| 2026-03-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-02 | Body height | 170 | cm | S |
| 2026-04-02 | Body weight | 53.4 | kg | S |
| 2026-04-02 | Body mass index (BMI) [Ratio] | 18.5 | kg/m2 | S |
| 2026-04-02 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-04-02 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-04-02 | Heart rate | 80 | /min | S |
| 2026-04-02 | Respiratory rate | 14 | /min | S |
| 2026-04-02 | Body temperature | 36.8 | Cel | S |
| 2026-04-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-30 | Body height | 170 | cm | S |
| 2026-04-30 | Body weight | 55.2 | kg | S |
| 2026-04-30 | Body mass index (BMI) [Ratio] | 19.1 | kg/m2 | S |
| 2026-04-30 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-04-30 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-04-30 | Heart rate | 74 | /min | S |
| 2026-04-30 | Respiratory rate | 14 | /min | S |
| 2026-04-30 | Body temperature | 36.7 | Cel | S |
| 2026-04-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-12 | Body height | 170 | cm | S |
| 2026-10-12 | Body weight | 57.2 | kg | S |
| 2026-10-12 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 2026-10-12 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-10-12 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-12 | Heart rate | 68 | /min | S |
| 2026-10-12 | Respiratory rate | 14 | /min | S |
| 2026-10-12 | Body temperature | 36.6 | Cel | S |
| 2026-10-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-20 | Body height | 170 | cm | S |
| 2026-04-20 | Body weight | 53.6 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 18.5 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 98 | /min | S |
| 2026-04-20 | Respiratory rate | 16 | /min | S |
| 2026-04-20 | Body temperature | 38.4 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-27 | Body height | 170 | cm | S |
| 2026-07-27 | Body weight | 56.6 | kg | S |
| 2026-07-27 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 2026-07-27 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-07-27 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-07-27 | Heart rate | 70 | /min | S |
| 2026-07-27 | Respiratory rate | 14 | /min | S |
| 2026-07-27 | Body temperature | 36.6 | Cel | S |
| 2026-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-16 | New patient visit for about three months of tiredness, weight loss, darkening skin, nausea and back ache, with blood tests and urgent endocrinology referral | finished | S |
| 2026-03-19 | Endocrinology consultation with a cosyntropin stimulation test, diagnosis, and start of replacement | finished | S |
| 2026-04-02 | Two-week review after starting replacement: electrolytes, cause, and autoimmune screening | finished | S |
| 2026-04-30 | Six-week review: electrolytes, renin, blood count, and recovery | finished | S |
| 2026-10-12 | Seven-month review: replacement, renin, thyroid, mood, and the closing of the differential | finished | S |
| 2026-04-20 | Same-day sick visit for streptococcal pharyngitis with stress dosing of hydrocortisone | finished | S |
| 2026-07-27 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Initial evaluation of tiredness, weight loss, darkening skin, low sodium and high potassium: blood count, metabolic panel, thyroid tests, ferritin, vitamin B12 and folate at the first visit; urgent 8 am cortisol and ACTH with a cosyntropin stimulation test within days; until then, salt freely, and go to the emergency department at once for vomiting, fainting, confusion or severe abdominal pain | completed | GL-ES-PAI-2016, GL-CMID-2026 | S |
| Urgent endocrinology consultation within three days to confirm or exclude primary adrenal insufficiency, start replacement if confirmed, and plan the search for the cause | completed | GL-ES-PAI-2016 | S |
| Replacement: hydrocortisone 10 mg on waking and 5 mg at 2 pm (15 mg a day) and fludrocortisone 0.1 mg each morning, adjusted by weight, energy, blood pressure lying and standing, salt craving and signs of over- or under-replacement, with sodium, potassium and plasma renin after any fludrocortisone change and at least yearly | completed | GL-ES-PAI-2016 | S |
| Written sick-day rules (double the hydrocortisone for fever above 38 °C, triple it above 39 °C, and inject 100 mg and call 911 for vomiting, inability to take tablets, or feeling faint), an emergency hydrocortisone injection kit with training, a steroid emergency card and a medical ID, reviewed at every visit | completed | GL-ES-PAI-2016 | S |
| Cause and differential: 21-hydroxylase antibodies at the two-week visit; adrenal CT and tuberculosis testing only if they are negative; examination for lymph nodes and spleen, LDH and a chest X-ray now, with CT of the chest, abdomen and pelvis if weight loss, fevers, night sweats or enlarged nodes persist once replacement is established | completed | GL-ES-PAI-2016 | S |
| Screening for associated autoimmune disease: TSH (normal at intake) at least yearly; vitamin B12, A1c, and celiac serology with total IgA; ask about periods at each visit and check FSH if they become irregular or stop | completed | GL-ES-PAI-2016, GL-ACG-CD-2023 | S |
| Anemia: ferritin, vitamin B12 and folate at intake; repeat the blood count on treatment and look further only if it does not recover | completed | GL-CMID-2026 | S |
| Streptococcal pharyngitis: amoxicillin 500 mg twice daily for ten days; hydrocortisone doubled under the sick-day rules until a day without fever and then back to the usual dose; fluids with salt; the emergency injection with a 911 call if she vomits or cannot take tablets; neck nodes rechecked at the six-week visit | completed | GL-ES-PAI-2016, GL-IDSA-GAS-2012 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| A diagnosis within one week of the first visit, with treatment started the same day if adrenal insufficiency is confirmed | 2026-03-19 | completed | Cosyntropin test three days after the first visit; replacement started the same day | S |
| No adrenal crisis and no emergency admission through the episode | 2026-10-12 | completed | No crisis or admission; one febrile illness managed at home with stress dosing | S |
| Sodium and potassium normal, renin in the upper normal range, and no postural drop by the six-week visit | 2026-04-30 | completed | Sodium 139 and potassium 4.4 mmol/L; renin 3.4 ng/mL/h; no postural drop | S |
| She can state the sick-day rules and give the emergency injection by the two-week visit | 2026-04-02 | completed | Stated the rules and gave a practice injection on a trainer | S |
| Weight back to her usual 57 kg, and energy for full mornings of writing, by six months | 2026-10-12 | completed | Weight 57.2 kg from 52.0; writing full mornings and walking several miles | S |